Computational Chemistry
Computational chemistry plays an essential role in the IACS drug discovery and optimization processes by identifying novel ways to improve binding affinity and selectivity of the compounds developed by the medicinal chemistry group. The computational group provides unique structural insights into the binding mode of novel inhibitors. Using advanced algorithms they are also able to virtually screen novel targets against millions of compounds to identify potential starting points for novel programs and predict potential metabolic or toxicity liabilities with lead compounds.
Newsletter
MD Anderson Hightlights
Conquest: IACS Infographic
Cancer Frontline: Institute of Medicine Elects Lynda Chin to Membership
Promise: Academia Meets Biotech in New Institute
Promise: Ronald DePinho Announces IACS
Conquest: Academic Insight, Industrial Execution
Cancerwise: Institute to Bring New Hope for Better Cancer Drugs
External Media Coverage
IACS Established
Governor’s press release
KUT
Houston Chronicle
Boston Globe
GSK Collaboration Announced
FierceBiotech
Drug Discovery News
Houston Business Journal
KUHF Radio Interview
BioWorld
Moon Shot Program Launched
Time Magazine: Cancer Dream Teams
Time Magazine: The Conspiracy To End Cancer
NDC Established
Houston Chronicle
Drug Discovery News
Houston Business Journal
Join our Team
Find your place on our dynamic team.
Contact Us
Institute for Applied Cancer Science
MD Anderson Cancer Center
1901 East Road
Houston TX 77054
Tel: 713-745-2600
For questions concerning collaborations or partnerships, please contact:
Eric Devroe
Executive Director of Strategic Alliances
EJDevroe@mdanderson.org
We need your help
Philanthropic support will provide IACS several critical advantages that will ultimately benefit cancer patients by providing them with novel treatments in a shorter timeframe. If you’re interested in advancing this transformative venture, please donate through the myGiving site.